• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

The Biosimilar War Is Not Over Yet

Article

Will Sandoz' biosimilar, first ever in the US, ever see the light of day?

While Sandoz was granted regulatory approval for it's Zarxio biosimliar, filgrastim-sndz, back in March, the product has not yet reached the market...and may not for a while if Amgen has it's way.

Amgen's Neupogen, approved by FDA in 1991, is a therapy to help increase cancer patients’ white blood cell counts and fight infections. The drug, which costs approximately $3000 for each chemotherapy cycle, generated $839 million in US sales last year for Amgen. Amgen is fighting to prevent Novartis AG, the parent company of Sandoz, from marketing the product, citing copyright issues with biologic manufacturing.

Arguments from both sides were heard in a Washington appeals court yesterday.

Read more on Bloomberg: http://bloom.bg/1Qabmy0

Related Videos
1 KOL is featured in this series.
Screenshot of Susan Wescott, RPh, MBA
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
5 KOLs are featured in this series.
4 KOLs are featured in this series
5 KOLs are featured in this series.
5 KOLs are featured in this series.
4 KOLs are featured in this series
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.